Introduction {#s1}
============

Pluripotent cells have the unique ability to differentiate into every cell type of an adult organism ([@bib50]). During mouse development, the embryo contains pluripotent cells in the epiblast until the onset of somitogenesis ([@bib55]; [@bib14]). Distinct pluripotent cell types can be isolated in culture from the preimplantation and postimplantation epiblast. Embryonic stem cells (ESCs) ([@bib20]; [@bib44]) from preimplantation embryos are termed 'naïve' pluripotent cells. Epiblast stem cells (EpiSCs) ([@bib68]; [@bib11]), commonly isolated from the post-implantation epiblast, are known as 'primed' pluripotent cells. Naïve and primed cells differ dramatically in responses to extracellular signals ([@bib50]). ESCs self-renew in response to a combination of leukaemia inhibitory factor (LIF) and either foetal calf serum (FCS), bone morphogenic protein (BMP) or Wnt ([@bib64]; [@bib81]; [@bib67]) and differentiate in response to fibroblast growth factor (FGF) ([@bib38]; [@bib66]). In contrast, FGF together with Nodal/Activin A are required for EpiSCs self-renewal ([@bib73]; [@bib26]).

Pluripotency is regulated by a pluripotency gene regulatory network (PGRN) ([@bib14]; [@bib23]; [@bib76]). While some transcription factors such as Esrrb and T (Brachyury) are associated more closely with naïve or primed pluripotent states respectively ([@bib22]; [@bib55]; [@bib70]), the core TFs of the PGRN, Nanog, Sox2 and Oct4 (the *Pou5f1* gene product, also referred as Oct3/4) are expressed in both naïve and primed pluripotent cells ([@bib51]; [@bib45]; [@bib6]; [@bib13]; [@bib32]; [@bib55]; [@bib22]; [@bib11]; [@bib68]). While the role of Sox2 has been extensively characterised in naïve cells ([@bib76]), its role in primed pluripotency is less well known.

Sox2 is a member of a family of twenty Sox TFs ([@bib58]; [@bib30]). All SOX proteins contain a High-Mobility-Group (HMG) box DNA-binding domain closely related to the founding member of the Sox family, SRY ([@bib37]). While some SOX proteins contain a transcriptional activation domain, others contain repression domains ([@bib71]; [@bib9]; [@bib4]). The paradigm of action for SOX proteins is that they bind to target gene sequences through a DNA-mediated interaction with a partner protein, to specify target gene selection ([@bib29]; [@bib60]; [@bib75]; [@bib30]). In pluripotent cells the principal interaction of SOX2 with OCT4 ([@bib3], [@bib4]) is considered to positively regulate expression of many pluripotency-specific genes including *Nanog*, *Oct4* and *Sox2* ([@bib69]; [@bib15]; [@bib54]; [@bib63]; [@bib39]). Loss of SOX2 in ESCs induces trophoblast differentiation, phenocopying OCT4 loss and supporting the idea of a mutually dependent mode of action ([@bib51]; [@bib45]).

Analysis of sequence conservation within the HMG box has divided the Sox family into eight groups that can be further divided into subgroups based on homology outside the HMG box ([@bib36]; [@bib31]). SOX1, SOX2 and SOX3 belong to the SOXB1 group and also contain transcriptional activation domains ([@bib71]; [@bib4]; [@bib9]; [@bib35]; [@bib48]; [@bib30]). SOXB1 proteins bind the same DNA sequence in vitro ([@bib29]; [@bib31]). Previous studies demonstrated that SOXB1 factors are co-expressed during embryonic development and can substitute for each other in different biological systems, both in vitro and in vivo ([@bib77]; [@bib52]; [@bib2]). Here, we investigate the requirements of naïve and primed pluripotent states for SOXB1 expression. Our results indicate that the essential requirement of SOXB1 function for naïve pluripotent cells extends to primed pluripotent cells. SOX3, which is highly expressed in primed pluripotent cells, functions redundantly with SOX2, rendering SOX2 dispensable in these cells. We further provide evidence that critical SOXB1 levels are required to specify the identity of cells exiting the naïve pluripotent state.

Results {#s2}
=======

A fluorescent reporter of SOX2 protein expression {#s2-1}
-------------------------------------------------

To investigate the expression of Sox2 in pluripotent cells, a live cell reporter that retained Sox2 function was prepared by replacing the *Sox2* stop codon with a T2A-H2B-tdTomato cassette ([Figure 1A](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Correctly targeted cells were identified by Southern analysis and are referred to as E14[T]{.ul}g2a-[S]{.ul}ox2-td[T]{.ul}omato (TST) cells ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Fluorescence microscopy of targeted cells showed a close correlation between SOX2 and tdTomato levels ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Moreover, tdTomato expression recapitulated the SOX2 expression pattern in chimeric embryos ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Targeted cells also showed the expected morphological differences when cultured in a combination of LIF plus inhibitors of MEK and GSK3β (LIF/2i), in LIF/FCS, in LIF/BMP or after passaging in Activin/FGF ([Figure 1A](#fig1){ref-type="fig"}). These results indicate that TST cells behave normally and provide a useful live cell report of Sox2 expression levels.

![Different roles of Sox2 in preimplantation and postimplantation pluripotency.\
(**A**) Expression of the Sox2-T2A-H2b-tdTomato (Sox2::HT) reporter from the endogenous *Sox2* allele in targeted TST18 cells. TST18 cells cultured in LIF/FCS/GMEMβ were replated in LIF/2i/N2B27 or LIF/BMP4/N2B27 for four passages or in Activin/FGF/N2B27 (Activin/FGF) for nine passages, examined microscopically (top) and assessed by flow cytometry (bottom); E14Tg2a cells were represented as a grey dashed line. (**B**) Three gates (**A, B, C**) were used to purify cells for microarray analysis. Gate C captured the Sox2::HT level in LIF/2i cultured ESCs. Gate B captured the overlapping Sox2::HT level in LIF/FCS, LIF/BMP and Activin/FGF cultured cells. Gate A captured the lower Sox2::HT level in Activin/FGF. (**C**) Principal component analysis of cells in different culture conditions, either unsorted or sorted using the gates indicated by brackets. (**D**) Despite similar Sox2::HT levels, no differentially expressed genes (DEGs, FDR = 0.1) were common to LIF/FCS-low and Activin/FGF-high cell populations. (**E**) RT-qPCR analysis of the indicated transcripts in ESCs (LIF/FCS, red bars) and EpiSCs (Activin/FGF, cultured for 16 passages, blue bars). Transcript levels were normalized to *Tbp* and plotted relative to ESCs. Error bars represent standard error of the mean (n = 3 to 4).](elife-27746-fig1){#fig1}

TST ESCs were next assessed by fluorescence microscopy and FACS. In LIF/2i, tdTomato expression was high and unimodal ([Figure 1A](#fig1){ref-type="fig"}). In LIF/FCS or LIF/BMP the same predominant high-expressing population was present but with a shoulder of reduced expression and a small number of tdTomato-negative cells, which appeared to coincide with morphologically differentiated cells ([Figure 1A](#fig1){ref-type="fig"}). In continuous culture in Activin/FGF, tdTomato expression was bimodal with the highest expression levels overlapping the lower expression levels seen in ESCs cultured in LIF/FCS or LIF/BMP ([Figure 1A,B](#fig1){ref-type="fig"}).

Gene expression in ESCs and EpiSCs expressing distinct Sox2 levels {#s2-2}
------------------------------------------------------------------

ESCs and EpiSCs expressing distinct Sox2 levels were separated by FACS according to the tdTomato level ([Figure 1B](#fig1){ref-type="fig"}). Microarray analysis was then used to compare gene expression in cells from different culture conditions expressing similar Sox2 levels and in cells from the same cultures expressing distinct Sox2 levels ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). Cells expressing the highest tdTomato levels in LIF/2i, LIF/FCS or LIF/BMP cultures were purified using gate C. The mid-level expression gate B enabled purification of the Sox2-low fraction of ESCs cultured in LIF/FCS or LIF/BMP as well as the highest Sox2-expressing EpiSCs. EpiSCs were also purified using the lower expression gate A. Re-sorting confirmed effective purification prior to RNA extraction and analysis ([Figure 1B](#fig1){ref-type="fig"}). Compared to the Sox2-high population, Sox2-low EpiSCs had upregulated differentiation markers. Transcripts expressed by Sox2-low EpiSCs differed from those expressed by Sox2-low ESCs ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}) suggesting that ESCs and EpiSCs have distinct differentiation propensities. ESCs from both LIF/BMP and LIF/FCS cultures sorted for highest tdTomato expression (gate C) were enriched for naïve pluripotency transcripts with mRNAs common to both (including *Nr5a2*, *Tbx3* and *Tcl1*) positively correlating to Sox2 in all samples ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). Moreover, principal component analysis indicated that these Sox2-high ESCs cluster together and separately from ESCs cultured in LIF/2i ([Figure 1C](#fig1){ref-type="fig"}) as seen by others ([@bib8]). More importantly, principal component analysis also showed that EpiSCs and ESCs expressing the same Sox2 level (gate B) were transcriptionally distinct ([Figure 1C](#fig1){ref-type="fig"}) and shared no commonly enriched mRNAs ([Figure 1D](#fig1){ref-type="fig"}). Thus, Sox2 levels alone do not dictate the distinction between ESC and EpiSC states.

Microarray and quantitative transcript analyses highlighted changes in Sox gene expression levels ([Figure 1E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}). Although other Sox gene expression changes occurred, the ability of SOXB1 proteins to function redundantly in ESC self-renewal ([@bib52]) prompted us to assess the capacity of SOXB1-related proteins to function more widely in pluripotent cells.

A subset of SOX family proteins can functionally replace *Sox2* in ESC self-renewal {#s2-3}
-----------------------------------------------------------------------------------

Recently, [@bib52] reported that ESC self-renewal could be maintained in the absence of SOX2 by expression of other SOXB1 and SOXG proteins ([@bib52]). We addressed the question of functional redundancy with Sox2 in ESCs using an independent *Sox2* conditional knockout (SCKO) ESC line ([@bib21]; [@bib24]). SCKO ESCs have one *Sox2* allele replaced by β-geo, the second allele flanked by *loxP* sites and constitutively express a tamoxifen-inducible Cre recombinase (CreER^T2^) ([Figure 2A](#fig2){ref-type="fig"}). SCKO ESCs were transfected with a plasmid in which constitutive Sox cDNA expression was linked to hygromycin B resistance and were either left untreated or were simultaneously treated with tamoxifen to excise *Sox2* ([Figure 2A](#fig2){ref-type="fig"}). ESC self-renewal was assessed after 8--10 days of hygromycin selection. Transfection of plasmids encoding transcriptional activator proteins of the SOXB1 family (SOX1, SOX2 or SOX3) enabled similar levels of ESC colony formation in the absence of *Sox2* ([Figure 2B,C](#fig2){ref-type="fig"}). In contrast, the SOXB2 proteins (SOX14 and SOX21), in which the SOXB DNA-binding domain is linked to transcriptional repression domains, did not direct undifferentiated ESC colony formation ([Figure 2C](#fig2){ref-type="fig"}). Of the other SOX proteins tested, only SOX15 showed any capacity to direct undifferentiated ESC colony formation ([Figure 2C](#fig2){ref-type="fig"}), as previously described ([@bib52]), possibly because it has the most similar DNA-binding domain to SOXB proteins ([@bib30]). These results indicate that ESC self-renewal requires the function of a SOX protein with a SOXB-like DNA-binding domain coupled to a transcriptional activating function.

![The ESC function of Sox2 can be substituted by SOXB1 and SOXG proteins.\
(**A**) Strategy for testing the ability of candidate Sox cDNAs to rescue ESC self-renewal upon *Sox2* deletion. *Sox2^fl/-^* (SCKO) ESCs were treated with 4-hydroxy-tamoxifen (4OHT) to induce nuclear localisation of CreER^T2^ and consequent *loxP*-mediated *Sox2* excision. Simultaneous transfection of test cDNAs linked to hygromycin phosphotransferase via an IRES (i) were tested for Sox2 complementation activity. (**B**) SCKO ESCs transfected with the indicated cDNAs were cultured in the presence of hygromycin B and in the absence (−4OHT) or presence (+4 OHT) of 4-hydroxyl-tamoxifen for 8 days before being fixed and stained for alkaline phosphatase (AP) activity. (**C**) Stained colonies were scored based on AP+ (undifferentiated), mixed or AP− (differentiated) morphology. Error bars represent standard error mean (n = 3). (**D**) RT-qPCR analysis of the rescuing transgenes in Sox1-, Sox2- and Sox3-rescued (S1R, S2R, S3R) ESC populations grown in the presence of 4-hydroxyl-tamoxifen as described in [Figure 2A,B](#fig2){ref-type="fig"}. RT-qPCR was performed using common primers designed across the CAG intron upstream of the rescuing transgene. Values were normalised over *Tbp* and expressed relative to S2R cells. Error bars represent the standard error of the mean (n = 3).](elife-27746-fig2){#fig2}

To further assess the ability of SOX proteins to sustain ESC self-renewal, we attempted to expand transfected cell populations. PCR analysis confirmed deletion of the *Sox2* conditional allele (400 bp) from expanded cell populations expressing SOX1, SOX2 or SOX3 ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Furthermore, SoxB1-rescued (S1R and S3R) SKO ESCs retained OCT4 and NANOG expression, similar to SCKO and Sox2-rescued SKO (S2R) ESCs ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). The transgene expression levels in ESC populations rescued by Sox1, 2 or 3 were assessed by quantitative transcript analysis using common primers across the CAG intron. This demonstrated that the Sox3 transgene mRNA was expressed at a higher level than the Sox1 or Sox2 transgenes ([Figure 2D](#fig2){ref-type="fig"}). These results confirm the findings of Niwa *et al.* in an independent cell line ([@bib52]).

*Sox3* is dispensable for both naïve and primed pluripotency {#s2-4}
------------------------------------------------------------

*Sox3* transcripts are present in ESCs at lower levels than Sox2 ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) and a previous report has suggested that Sox3 is dispensable for ESC self-renewal ([@bib61]; [@bib62]). To directly assess this possibility, and as a first step to determining whether Sox3 is required in EpiSCs, CRISPR/Cas9 was used to delete the *Sox3* gene from male E14Tg2a ESCs ([@bib28]; [@bib17]) using two small guide RNAs (sgRNA1 and sgRNA2) ([Figure 3A](#fig3){ref-type="fig"}). After targeting, E14Tg2a ESCs were plated at low density and single clones were isolated. PCR genotyping using primers flanking the predicted Cas9 cut sites ([Figure 3A](#fig3){ref-type="fig"}) identified two clones (S3KO8 and S3KO35) in which *Sox3* had been deleted ([Figure 3B](#fig3){ref-type="fig"}). Replating at clonal density indicated that both clones retained an efficient self-renewal ability ([Figure 3C](#fig3){ref-type="fig"}). Moreover, both clones had unchanged levels of *Nanog*, Oct4 and *Sox2* mRNAs ([Figure 3D](#fig3){ref-type="fig"}). These findings indicate that *Sox3* is dispensable for ESC self-renewal, confirming previously unpublished data ([@bib61]).

![*Sox3* is dispensable for pluripotent cell maintenance.\
(**A**) Schematic representation of the *Sox3* locus on the mouse X chromosome showing the CRISPR/Cas9 strategy for the generation and genotyping of *Sox3* knockout ESCs. The positions of sgRNA1 and sgRNA2 used for the deletion of the *Sox3* locus are indicated alongside the positions of PCR primers used for genotyping. (**B**) PCR genotyping of parental ESCs (E14Tg2a), a wild-type clone (37) and two *Sox3* knockout clones (S3KO8, S3KO35) after CRISPR/Cas9 targeting of the *Sox3* locus. Band sizes for the WT (\~2 kb) and targeted (\~600 bp) alleles are shown. (**C**) Alkaline phosphatase staining in S3KO8, S3KO35 and WT (Clone 37 and E14Tg2a) ESCs grown at clonal density for 7 days. (**D--E**) RT-qPCR analysis of the indicated transcripts in wild-type E14Tg2a and *Sox3^-/Y^* (S3KO8, S3KO35) ESCs (**D**) and EpiSCs (**E**) derived by serial passaging (\>10 passages) in Activin/FGF conditions. Error bars represent standard error of the mean (n = 3). (**F-G**) Immunofluorescence staining of SOX2 (**F**), SOX3 (**G**) and OCT4 proteins in E14Tg2a and *Sox3^-/Y^* EpiSCs (S3KO8, S3KO35). Scale bar, 100 μm.](elife-27746-fig3){#fig3}

Next, the requirement of SOX3 for primed pluripotency was determined by examining the ability of the above *Sox3* knockout ESC clones, together with parental E14Tg2a ESCs, to be converted to EpiSCs by serial passaging in Activin and FGF ([@bib26]). Quantitative transcript analysis at passage 12 indicated similar levels of *Sox2*, Oct4 and *Nanog* mRNA expression in wild-type and *Sox3* knockout EpiSCs ([Figure 3E](#fig3){ref-type="fig"}). In contrast, *Sox1* mRNA levels were reduced in both *Sox3* knockout clones ([Figure 3E](#fig3){ref-type="fig"}) and T (Brachyury) was more variably expressed ([Figure 3E](#fig3){ref-type="fig"}). The ability of EpiSCs to self-renew in the absence of SOX3 was maintained over 25 passages without affecting SOX2 and OCT4 protein expression or EpiSC morphology ([Figure 3F,G](#fig3){ref-type="fig"}). These data demonstrate that both naïve and primed pluripotent cells can self-renew in the absence of Sox3.

*Sox2* is dispensable for the maintenance of primed pluripotency {#s2-5}
----------------------------------------------------------------

To investigate whether primed pluripotency can be maintained in the absence of SOX2, SCKO EpiSCs were derived by in vitro culture of SCKO ESCs ([@bib26]). SCKO EpiSCs were then transfected with a plasmid encoding both Cre recombinase and tdTomato ([Figure 4A](#fig4){ref-type="fig"}), since the CAG CreERT^2^ transgene ([Figure 2A](#fig2){ref-type="fig"}) had been silenced during the EpiSC transition. After 12--24 hr, tdTomato-positive EpiSCs were sorted by FACS and re-plated at low cell density to allow expansion of single clones. PCR genotyping of expanded EpiSC clones revealed that the *loxP*-flanked *Sox2* allele had been excised generating *Sox2^-/-^* (SKO) clones ([Figure 4A](#fig4){ref-type="fig"}). Immunoblot analysis confirmed that these SKO clones did not express SOX2 protein and that *Sox2^fl/-^* EpiSCs expressed SOX2 at 50% the level of *Sox2^+/+^* EpiSCs ([Figure 4B](#fig4){ref-type="fig"}). Moreover, NANOG protein levels were similar to parental SCKO EpiSCs or wild-type E14Tg2a EpiSCs ([Figure 4B](#fig4){ref-type="fig"}). *Sox2*^-/-^ EpiSCs retained an undifferentiated morphology ([Figure 4C](#fig4){ref-type="fig"}) and immunostaining confirmed the absence of SOX2 and continued OCT4 expression compared to parental SCKO EpiSCs ([Figure 4D](#fig4){ref-type="fig"}). Quantitative transcript analysis of Oct4, *Nanog* and *Sox2* , indicated that, while *Sox2* mRNA was absent from *Sox2^-/-^* EpiSCs, both Oct4 and *Nanog* mRNA levels were unaffected ([Figure 4E](#fig4){ref-type="fig"}). This suggests that the core pluripotency gene regulatory network remains active even in the absence of SOX2 and that, in contrast to the situation with naïve pluripotency, primed pluripotency is not critically dependent upon Sox2.

![*Sox2* is dispensable for the maintenance of EpiSCs.\
(**A**) Strategy for *Sox2* deletion in EpiSCs. *Sox2^fl/-^* (SCKO) EpiSCs were transfected with pCMV-tdTomato-T2A-Cre. After 12--24 hours, cells were sorted for tdTomato expression and re-plated in the presence of ROCK inhibitor. Clones were picked and expanded before genotyping by PCR as indicated in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} . SCKO EpiSCs were also transfected with pCMV-tdTomato (lacking Cre). Expanded clones were numbered as indicated. (**B**) Immunoblot analysis of E14Tg2a, *Sox2^fl/-^* (SCKO) and *Sox2^-/-^* (SKO) EpiSCs showing that SOX2 protein (red) is reduced in SCKO and absent in SKO EpiSCs. NANOG protein levels (green) were unaffected. Protein levels (normalized to the βactin level) are graphed below. (**C**) Bright-field morphology of E14Tg2a and SKO4 EpiSCs after 2 weeks (8 passages) in culture. Scale bar, 100 μm. (**D**) Immunofluorescence staining of SOX2 and OCT4 in SCKO and SKO6 EpiSCs. Scale bar, 100 μm. (**E**) RT-qPCR analysis of the indicated transcripts in E14Tg2a, *Sox2^fl/-^* (SCKO) and *Sox2^-/-^* (SKO) EpiSCs. Clone numbers are indicated. Error bars represent the standard error of the mean (n = 2 to 3).](elife-27746-fig4){#fig4}

The ability of SOXB1 proteins to substitute for one another in ESCs raised the hypothesis that functional redundancy between SOX2 and SOX3 may be responsible for the maintenance of pluripotency in primed EpiSCs. Expression of both *Sox1* and *Sox3* mRNAs was increased in EpiSCs compared to ESCs ([Figure 1E](#fig1){ref-type="fig"}). Examination of *Sox2*^-/-^ EpiSCs showed that while Sox1 mRNA expression was reduced, Sox3 mRNA levels were elevated compared to control cells ([Figure 4E](#fig4){ref-type="fig"}). This suggests that Sox3 expression might functionally compensate for the lack of Sox2 in *Sox2^-/-^* EpiSCs, as is the case in *Sox2*-null E14.5 forebrain, where a 2-fold increase in *Sox3* mRNA was detected ([@bib46]). Alternatively, SOXB1 proteins may be irrelevant for EpiSC self-renewal. To distinguish between these possibilities we developed an approach to gene disruption using CRISPR/Cas9.

Testing the functional effects of Sox ORF disruption using CRISPR/Cas9 {#s2-6}
----------------------------------------------------------------------

To examine the functional dependence of cells on Sox genes, a CRISPR/Cas9 approach was developed and tested initially using *Sox2*. Insertions or deletions (indels) into the *Sox2* open reading frame (ORF) were introduced immediately upstream of the sequence encoding the SOX2 HMG domain ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Out-of-frame indels in this position are expected to abolish the DNA-binding ability of any aberrant protein that might still be produced. The frequency and length of indels induced by CRISPR/Cas9-mediated targeting of the endogenous *Sox2* locus were investigated by TIDE ([T]{.ul}racking of [I]{.ul}ndels by [De]{.ul}composition) analysis ([@bib10]). *Sox2^fl/-^* SCKO ESCs that constitutively express Sox1, Sox3 or GFP (generated in [Figure 2B](#fig2){ref-type="fig"} in the absence of tamoxifen) were analysed. If, as expected, Sox1 or Sox3 can rescue self-renewal, then such cells would carry both in-frame and out-of-frame (deleterious) indels ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). In contrast, if ESC self-renewal relies on the remaining *Sox2* allele, as anticipated in the case of SCKO ESCs constitutively expressing GFP, then cells carrying deleterious indels should be eliminated from the population. In this case, the only modifications present would be non-deleterious in-frame indels ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). SCKO ESCs expressing Sox1, Sox3 or GFP were transfected with a plasmid encoding the sgRNA and eCas9. Cells were selected, genomic DNA isolated, PCR amplified, sequenced and analysed by TIDE. The population of SCKO ESCs expressing GFP contained *Sox2* loci with no out-of-frame indels detected ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). In contrast, SCKO ESCs constitutively expressing Sox1 or Sox3 tolerated out-of-frame, deleterious indels at *Sox2* (size +1,--10, −13) ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). These results show that indel analysis can be applied to study functional redundancy between SOXB1 group members in the maintenance of pluripotent cells.

*Sox2* and *Sox3* are functionally redundant for the maintenance of EpiSCs {#s2-7}
--------------------------------------------------------------------------

Having established the utility of CRISPR/Cas9-mediated indel induction for gene function analysis, a similar strategy was applied to *Sox2^-/-^* EpiSCs to determine whether SOXB1 proteins operate in a functionally redundant way to maintain EpiSCs. Since *Sox2^-/-^* EpiSCs showed an increase in *Sox3* mRNA expression upon deletion of the second *Sox2* allele, we focussed on *Sox3*, which is X-linked and thus present in only one copy in these male EpiSCs (*Sox3^+/Y^*). Two sgRNAs (sgRNA1 and 2) were designed to independently target the *Sox3* ORF immediately upstream of the sequence encoding the HMG DNA-binding domain and tested individually ([Figure 5A](#fig5){ref-type="fig"}). TIDE analysis ([Figure 5B](#fig5){ref-type="fig"}) showed that in control EpiSCs expressing endogenous Sox2 (E14Tg2a and SCKO) both in frame and out of frame indels within *Sox3* were detected using either sgRNA ([Figure 5C](#fig5){ref-type="fig"}). In contrast, two independent *Sox2^-/-^* EpiSC lines (SKO1, SKO6) retained only in frame deletions that did not disrupt the SOX3 HMG box ([Figure 5C](#fig5){ref-type="fig"}). Together with earlier results on *Sox2^-/-^* EpiSCs ([Figure 4](#fig4){ref-type="fig"}) and *Sox3^-/Y^* EpiSCs ([Figure 3](#fig3){ref-type="fig"}), these data indicate that EpiSCs lacking either *Sox2* or *Sox3* alone can be maintained, while cells lacking both SOX2 and SOX3 proteins are lost. Therefore, EpiSC self-renewal requires SOXB1 function, and this can be provided by the expression of either endogenous *Sox2* or *Sox3*.

![Sox3 indel analysis in *Sox2^-/-^* EpiSCs.\
(**A**) Schematic representation of the Sox3 ORF with the HMG box highlighted in dark blue. The amino-acid positions of the HMG box relative to the start (ATG) codon of the ORF are shown. The positions of the sgRNAs 1 and 2 used are represented as black bars. (**B**) Experimental design for Sox3 indel analysis in *Sox2^-/-^* EpiSCs. (**C**) Indel analysis performed using the TIDE tool (<https://tide-calculator.nki.nl/>) in two *Sox2^-/-^* EpiSC lines (SKO1 and SKO6), in the parental *Sox2^fl/-^* (SCKO) EpiSCs and in control E14Tg2a EpiSCs using Sox3 sgRNAs 1 and 2. Histograms represent indel frequency and size. Black bars indicate the frequency of unmodified (WT) alleles; grey bars indicate significant in frame indels and red bars indicate significant out of frame indels (p\<0.001). Non-significant (n/s, p≥0.001) indels are not shown.](elife-27746-fig5){#fig5}

Modulating SOXB1 levels affects differentiation and can prevent capture of primed pluripotency {#s2-8}
----------------------------------------------------------------------------------------------

Since *Sox2* and *Sox3* transcript levels change during ESC to EpiSC differentiation, this raised the question of their importance for attainment of a primed pluripotent state. ESCs that delete *Sox2* differentiate to trophectoderm ([@bib45]), while ESCs that continue expressing high SOX2 protein levels during differentiation are biased towards neural fates ([@bib83]). To assess the effect of increasing the SOXB1 concentration upon differentiation, we examined three clones overexpressing either SOX2 ([Figure 6](#fig6){ref-type="fig"}) or SOX3 ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), generated using the approach outlined in [Figure 2A](#fig2){ref-type="fig"}. When placed in an EpiSC differentiation protocol, both SOX2- and SOX3-overexpressing clones showed reduced expression of Oct4, *Nanog* and *Nr5a2* transcripts as well as increased expression of *Sox1*, Mash1 (the *Ascl1* gene product) and *Pax6* transcripts ([Figure 6A](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Examination of SOX2-overexpressing clones in Activin/FGF showed neural-like cellular morphology ([Figure 6B](#fig6){ref-type="fig"}) and βIII-tubulin-positive axonal processes ([Figure 6C](#fig6){ref-type="fig"}). These findings indicate that while high SOXB1 levels are tolerated by ESCs, a decreased dosage of SOXB1 is essential for ESCs to transit effectively to an EpiSC state and avoid ectopic neural differentiation.

![Increased SOXB1 levels skew ESC differentiation towards the neural lineage.\
(**A**) Schematic diagram showing the experimental plan. RT-qPCR analysis of the indicated transcripts in SCKO cells stably transfected and rescued with a Sox2 transgene (12--24 hr prior to a 24 hr treatment with 4OHT) (termed [S]{.ul}ox[2-r]{.ul}escued, S2R cells). Cells were grown in LIF/FCS conditions or differentiated in Activin/FGF conditions for 13 days (P2). Transcript levels were normalized to *Tbp* and plotted relative to SCKO ESCs. Error bars represent standard error of the mean (n = 3 to 5). (**B**) Bright field images of the indicated cells maintained in LIF/FCS or differentiated in Activin/FGF conditions (P2) . Scale bar, 100 μm. (**C**) Immunofluorescence staining of the neural marker βIII-tubulin (cyan) in cells differentiated in Activin/FGF conditions (P2); DAPI represented in grey. Scale bar, 100 μm.](elife-27746-fig6){#fig6}

The SoxB1 requirements during neural differentiation of ESCs were next assessed. Initially, we compared *Sox2^+/+^* ESCs previously cultured in LIF/FCS or LIF/2i during neural differentiation induced by culture in N2B27 medium ([@bib80]; [@bib81]). Our results indicate a more rapid induction of a Sox1-GFP reporter ([@bib5]) and *Sox1* mRNA from LIF/FCS cultures than from LIF/2i cultures ([Figure 7A](#fig7){ref-type="fig"}). The Sox1-GFP kinetics from 2i/LIF cultures observed here agree with those reported ([@bib43]), although this study noted a slower induction of Sox1-GFP from FCS/LIF cultures. However, as the timing of Sox1-GFP induction from FCS/LIF cultures in previous studies from the same group ([@bib81]) was consistent with the timings reported here, further differentiation experiments were initiated from LIF/FCS. Expression of pluripotency markers *Nanog* and *Nr5a2* was decreased in the neural differentiation protocol, although with lower efficiency in *Sox2^fl/-^* ESCs than in control *Sox2^+/+^* cells, while *Fgf5* was induced in both ([Figure 7B](#fig7){ref-type="fig"}). Strikingly, *Sox1*, Mash1 and *Pax6* mRNAs were induced in *Sox2^+/+^* but not *Sox2^fl/-^* cells ([Figure 7B](#fig7){ref-type="fig"}), and an increase in *Sox3* was not sustained. These data indicate that a SOXB1 level above that present in *Sox2^fl/^*^-^ cells is required to enable ESCs to undergo neural differentiation in vitro. Furthermore, the expression of *Fgf5* suggests that *Sox2^fl/-^* cells attain some aspects of an early post-implantation identity ([Figure 7B](#fig7){ref-type="fig"}). This contrasts with the neural differentiation observed in *Sox2^+/-^* mouse embryos ([@bib6]; [@bib62]; [@bib21]), suggesting that compensatory mechanisms other than SOXB1 redundancy exist in the embryo.

![Decreased SOX2 levels prevent ESC differentiation into neurons.\
(**A**) (TOP) Schematic diagram showing experimental plan for neural differentiation. (MIDDLE) Sox1-GFP ([@bib5]) expression in 46C cells cultured in LIF/FCS (green) or LIF/2i (purple) and for the indicated number of hours in N2B27 neural differentiation medium were assessed by flow cytometry. The positive (+) gate was set above the GFP expression level observed in 46C ESCs. The error bars indicate the standard error of the mean (n = 4). (BOTTOM) RT-qPCR analysis of *Sox1* mRNA level in 46C cells during neural differentiation. Error bars indicate the standard error of the mean (n = 2). (**B**) RT-qPCR analysis of the indicated transcripts in differentiating E14Tg2a (E14, *Sox2^+/+^*) and SCKO (*Sox2^fl/−^*) cells. Transcript levels were normalized to *Tbp*. Error bars represent standard error of the mean (n = 3). (**C**) Immunofluorescence staining of the neural marker βIII-tubulin (green) in *Sox2^+/+^* E14Tg2a (E14), H2.14 and H2.17 ESCs, and in *Sox2^+/-^* SCKO, H2.1 and BH1.21 ESCs differentiated in N2B27 medium for 4 days; DAPI represented in blue. Scale bar, 100 μm. (**D**) Immunofluorescence staining of the neural marker βIII-tubulin (green) in *Sox2^+/-^*and H2.1 ESCs differentiated in N2B27 medium for 4 days in the presence or in the absence of the LDN-193189 BMP inhibitor (BMPi), of the SB-431542 Nodal inhibitor (NODi) and of recombinant bFGF; DAPI represented in blue. Scale bar, 100 μm.](elife-27746-fig7){#fig7}

To eliminate the possibility that the neural differentiation defect in SCKO cells resulted from a defect unrelated to *Sox2*, CRISPR/Cas9 was used to introduce indels in the *Sox2* ORF in E14Tg2a ESCs. Using independent sgRNAs, two *Sox2^+/-^* clones were isolated. Clone H2.1 carried an 8 bp deletion on one *Sox2* allele; clone BH1.21 carried a 10 bp deletion on one allele and a 3 bp deletion on the other allele ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). Two additional clones in which the *Sox2* alleles were not modified (H2.14, H2.17) were used as controls. The −8 and −10 deletions cause frame-shifts introducing stop codons, while the −3 bp deletion is likely to be functionally neutral as it occurs N-terminal to the HMG domain ([Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). Placing *Sox2^+/+^* ESCs (H2.14, H2.17 and E14Tg2a) in a neural differentiation protocol produced βIII-tubulin positive neurons ([Figure 7C](#fig7){ref-type="fig"}). In contrast, no βIII-tubulin positive cells were detected from parallel treatments of H2.1, BH1.21 and SCKO *Sox2^+/-^* ([Figure 7C](#fig7){ref-type="fig"}). This establishes that the lack of a functional *Sox2* allele impairs effective neural differentiation of ESCs.

Neural differentiation of pluripotent cells is stimulated by FGF ([@bib81]; [@bib80]) and inhibited by both BMP and Nodal/Activin ([@bib79]; [@bib74]; [@bib73]; [@bib26]). To determine whether perturbations in these pathways could overcome the neural differentiation defect of *Sox2^+/-^* ESCs, H2.1 and SCKO cells were placed in the neural differentiation protocol supplemented with either recombinant bFGF or inhibitors of BMP or Nodal. Additional FGF, or inhibition of Nodal alone, was without effect, while BMP inhibition resulted in only a few βIII-tubulin-positive cells ([Figure 7D](#fig7){ref-type="fig"}). However, simultaneous BMP and Nodal inhibition enabled *Sox2^+/-^* ESCs to form βIII-tubulin-positive cells ([Figure 7D](#fig7){ref-type="fig"}). These results indicate that a reduction in SOX2 levels in ESCs enhances the response of cells to endogenous BMP and Nodal signalling, preventing effective neural differentiation.

To further investigate the effects of modulating SoxB1 gene dosage upon ESC differentiation, *Sox3^-/Y^* ESCs were generated by CRISPR/Cas9 mediated gene deletion from heterozygous *Sox2^fl/-^* ESCs (SCKO). PCR genotyping identified two *Sox2^fl/-^; Sox3^-/Y^* ESC clones (\#36 and \#37) ([Figure 8A](#fig8){ref-type="fig"}). Quantitative transcript analysis showed that while *Sox2^fl/-^* ESCs had an expected reduction in *Sox2* mRNA and unchanged levels of *Sox1* and *Sox3* mRNAs compared to E14Tg2a ESCs, deletion of *Sox3* from *Sox2^fl/-^* ESCs increased *Sox1* and surprisingly, also *Sox2* mRNA to a level similar to that present in E14Tg2a ESCs ([Figure 8B](#fig8){ref-type="fig"}). These data suggest cross-regulatory interactions between SoxB1 members in which SOX3 protein represses *Sox1* and *Sox2*, either directly or indirectly, in ESCs ([Figure 8B](#fig8){ref-type="fig"}). However, as *Sox3* deletion in *Sox2^+/+^* ESCs did not increase *Sox1* and *Sox2* mRNA levels ([Figure 3D](#fig3){ref-type="fig"}) this suggests that the repressive effect of SOX3 on *Sox2* is sensitive to the SOX2 protein concentration.

![*Sox2*/*Sox3* requirements during EpiSCs differentiation.\
(**A**) Genotyping analysis of the *Sox3* locus in E14Tg2a (E14, *Sox2^+/+^*), SCKO (*Sox2^fl/-^*) ESCs (∼2 kb band) and in two *Sox2^fl/-^; Sox3^-/Y^* ESC clones (\#36 and \#37) derived after deletion of the *Sox3* locus (∼600 bp band). Gene targeting was performed following the strategy depicted in [Figure 3A](#fig3){ref-type="fig"}. (**B**) RT-qPCR analysis of the indicated transcripts in E14Tg2a ESCs (E14, *Sox2^+/+^*), SCKO ESCs (*Sox2^fl/-^*) and in two *Sox2^fl/-^; Sox3^-/Y^* ESC clones (\#36 and \#37). mRNA levels were normalised over *Tbp* and plotted relative to E14Tg2a. Error bars indicate the standard error of the mean (n = 3). (**C**) RT-qPCR analysis of the indicated transcripts in SCKO cells (*Sox2^fl/-^*) and in two *Sox2^fl/-^; Sox3^-/Y^; Sox2^fl/-^* clones (\#36 and \#37) grown in LIF/FCS condition and in Activin/FGF conditions for 2 passages (P2). mRNA levels were normalised to *Tbp* and plotted relative to ESCs (LIF/FCS). Error bars indicate the standard error of the mean (n = 3). (**D**) RT-qPCR analysis of the indicated transcripts in SCKO cells (*Sox2^fl/-^*) and in two *Sox2^fl/-^; Sox3^-/Y^* clones (\#36 and \#37) grown in LIF/FCS condition and in neural differentiation medium (N2B27) for the indicated number of hours. mRNA levels were normalised to *Tbp* and plotted relative to ESC (LIF/FCS). Error bars indicate the standard error of the mean (n = 3).](elife-27746-fig8){#fig8}

Next, the ability of *Sox2^fl/-^; Sox3^-/Y^* ESCs to transition to primed pluripotency was assessed by passaging in Activin/FGF. Whereas *Sox2^fl/-^* EpiSCs could be successfully established and maintained ([Figure 4](#fig4){ref-type="fig"}), *Sox2^fl/-^; Sox3^-/Y^* cells displayed a differentiated morphology within two passages. Quantitative transcript analysis showed that in comparison to *Sox2^fl/-^* cells, *Sox2^fl/-^; Sox3^-/Y^* cells induced less *Fgf5* but more Mash1 and *Pax6* ([Figure 8C](#fig8){ref-type="fig"}). These data suggest that while primed pluripotency can be maintained in the absence of either *Sox2* or *Sox3*, the transition from a naïve ESC state to a primed EpiSC state does not occur effectively when *Sox3* is absent and the *Sox2* gene dosage is halved. Notably, compared to *Sox2^fl/-^* ESCs, *Sox2^fl/-^; Sox3^-/Y^* ESCs have the same *Sox2* mRNA level as *Sox2*^+/+^ ESCs and *Sox1* mRNA is increased \>10 fold ([Figure 8B](#fig8){ref-type="fig"}). Such an increase in *Sox1* mRNA expression is sufficient to enforce neural differentiation following LIF withdrawal ([@bib83]).

The increased levels of *Sox1* and *Sox2* mRNAs in LIF/FCS ([Figure 8B](#fig8){ref-type="fig"}), together with the increased levels of neural differentiation markers during EpiSC induction of *Sox2^fl/-^; Sox3^-/Y^* ESCs ([Figure 8C](#fig8){ref-type="fig"}), prompted us to examine the behaviour of *Sox2^fl/-^; Sox3^-/Y^* ESCs during neural differentiation. While *Sox2^+/-^* ESCs did not effectively undergo neural differentiation ([Figure 7](#fig7){ref-type="fig"}), deletion of *Sox3* from *Sox2^fl/-^* ESCs was sufficient to rescue neural differentiation as judged by induction of *Sox1*, Mash1 and *Pax6* mRNAs and of the βIII-tubulin protein ([Figure 8D](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). This is likely a secondary consequence of the increase in *Sox2*/*Sox1* mRNA expression in *Sox2^fl/-^* ESCs resulting from *Sox3* deletion ([Figure 8B](#fig8){ref-type="fig"}). The two *Sox2*^+/+^; *Sox3^-/Y^* ESC clones ([Figure 3A](#fig3){ref-type="fig"}) were able to differentiate into neural cells with similar efficiency to parental cells as shown by induction of *Sox1*, Mash1 and *Pax6* mRNAs ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}) and appearance of βIII-tubulin-positive cells ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}).

These data demonstrate that altering the SoxB1 genetic composition by deletion of *Sox3* and elimination of one functional *Sox2* allele induces a transcriptional de-regulation of the remaining *SoxB1* alleles. The increased mRNA levels of *Sox1* and *Sox2* are then sufficient to rescue neural differentiation of *Sox2^fl/-^* ESCs but also impair the ability of *Sox2^fl/-^; Sox3^-/Y^* ESCs to be captured as primed EpiSCs.

Discussion {#s3}
==========

Our examination of SoxB1 function in pluripotent cells extends previous findings that SOXB1 proteins can act redundantly in ESCs ([@bib52]) and during somatic cell reprogramming ([@bib47]) by showing that in EpiSCs, SOX2 and SOX3 proteins are functionally redundant within an altered PGRN. Functional redundancy implies that we can consider the total SOXB1 complement as a key factor in the outcomes selected by cells genetically engineered to express varying combinations of functional *SoxB1* alleles. In particular, a broad range of SOXB1 levels are tolerated by ESCs. However, upon exit from naïve pluripotency, low SOXB1 levels permit entry to the EpiSC state, while high levels enforce neural differentiation ([Figure 9](#fig9){ref-type="fig"}). We have also uncovered cross-regulatory relationships between Sox3 and the other SoxB1 members, that we hypothesise act to maintain an adequate SOXB1 level.

![Dependence of cell fate potential of ESCs on the total SOXB1 concentration.\
The overall SOXB1 concentration inferred from SoxB1 transcript levels in different *SoxB1* mutant cell lines. Naïve ESCs self-renew in a wide range of SOXB1 concentrations. However, only ESCs with approximately wild-type SOXB1 levels can differentiate towards both primed EpiSCs and neural cells. ESCs with increased SOXB1 concentrations are poised towards neural differentiation, preventing their capture as primed EpiSCs in FGF/ActivinA. Decreased SOXB1 concentrations are insufficient to enable neural differentiation due to increased activity of neural antagonists (BMP and Nodal). A further reduction in SOXB1 is tolerated in the primed state due to SOX2/SOX3 functional redundancy but complete loss of the predominant SoxB1 forms is incompatible with self-renewal of both naïve and primed pluripotent cells. Depicted below are diagrams of pre- (E3.5) and postimplantation (E5.5 and E7.5) mouse embryos indicating the published expression patterns of SoxB1 mRNAs ([@bib77]; [@bib72]; [@bib6]; [@bib12]), and the areas of BMP/Nodal signalling and inhibition during gastrulation ([@bib16]; [@bib7]; [@bib33]; [@bib42]; [@bib57]; [@bib53]; [@bib40]; [@bib56]).](elife-27746-fig9){#fig9}

SOXB1 function in primed pluripotent cells is provided by SOX2 and SOX3 {#s3-1}
-----------------------------------------------------------------------

In ESCs *Sox2* mRNA is expressed at much higher levels than either *Sox1* or *Sox3*, and thus, in spite of redundancy, Sox2 can be considered to provide the dominant SOXB1 function in ESC pluripotency. However, even though *Sox2* is also the most abundant *SoxB1* transcript in EpiSCs, functional properties of the PGRN have changed. While *Sox2* mRNA levels in EpiSCs are lower than in ESCs, *Sox3* levels are increased, and SoxB1 function is provided redundantly by Sox2 and Sox3. *Sox1* mRNA levels are also increased in these cells. The ability of Sox1 or Sox3 to substitute functionally for Sox2 in ESCs might suggest that Sox1 could also function redundantly with Sox2 to maintain EpiSCs. However, Sox1 may be less relevant to pluripotency as, unlike Sox2 and Sox3, which are widely expressed in the pluripotent postimplantation epiblast, Sox1 expression is uniquely associated with neural fate in the epiblast ([@bib77]; [@bib72]; [@bib12]; [Figure 9](#fig9){ref-type="fig"}). Indeed, Sox1 expression in EpiSC populations is associated with neural committed cells ([@bib70]).

SOXB1 redundancy in vivo {#s3-2}
------------------------

In the seminal *Sox2* deletion study ([@bib6]), *Sox2^-/-^* embryos fail to develop a postimplantation epiblast. This was hypothesised to be due to the fact that neither Sox1 nor Sox3 were expressed sufficiently at the time of embryonic failure and therefore no redundantly acting SOXB1 protein could compensate for the SOX2 absence. Additional instances of potential SoxB1 redundancy have been reported in vivo. Replacement of an endogenous *Sox2* allele with a Sox1 ORF produced no phenotype, suggestive of functional interchangeability ([@bib19]). SOXB1 redundancy is likely to be evolutionarily conserved since in the chick, Sox2 and Sox3 both promote development of ectoderm and neurectoderm at gastrulation, although interestingly, in this case Sox3 expression occurs before Sox2 ([@bib1]). Moreover, while genetic knock-ins have shown that placement of Sox2 ORF at the *Sox3* locus can rescue pituitary and testes phenotypes caused by *Sox3* deletion ([@bib2]), the effects on pluripotent cells were not assessed. It is therefore interesting that while *Sox3^-/Y^* mice can be viable, on a 129 genetic background they exhibit gastrulation-stage lethality ([@bib62]; [@bib2]). This suggests that aspects of the regulation of SoxB1 expression that we show here to be important in vitro could also contribute to strain-specific differences in the timing or regulation of SOXB1 activity in vivo. Further studies will be required to establish the extent to which SOXB1 proteins can substitute genetically for one another in pluripotent cells in vivo.

Low SOXB1 levels permit entry to the EpiSC state {#s3-3}
------------------------------------------------

Our results indicate that the total SoxB1 transcript level in ESCs needs to be reduced to enable entry into the EpiSC state rather than neural differentiation ([Figure 9](#fig9){ref-type="fig"}). *Sox2*^+/-^ ESCs placed in a neural differentiation protocol showed a reduced down-regulation of pluripotency markers (*Nanog* and *Nr5a2*) and failed to induce markers of neural differentiation. Surprisingly however, deletion of *Sox3* from SCKO cells to produce *Sox2^fl/-^; Sox3^-/Y^* ESCs restored neural differentiation capacity ([Figure 8D](#fig8){ref-type="fig"}). Moreover, placement of *Sox2^fl/-^; Sox3^-/Y^* ESCs in an EpiSC differentiation protocol resulted in a skewing of differentiation towards a neural identity as indicated by loss of *Nanog*, *Nr5a2* and *Fgf5* transcripts, and increase in mRNAs for neural differentiation markers ([Figure 8C](#fig8){ref-type="fig"}). This paradoxical behaviour may be explained by the fact that both *Sox1* and *Sox2* mRNAs increase upon elimination of *Sox3* from *Sox2^fl/-^* ESCs ([Figure 8B](#fig8){ref-type="fig"}). Interestingly, reciprocal repression of *Sox3* by SOX2 also occurs in EpiSCs ([Figure 4E](#fig4){ref-type="fig"}). Unravelling the regulatory relationships between *SoxB1* genes is a relevant point for future studies.

High SOXB1 levels enforce neural differentiation {#s3-4}
------------------------------------------------

Previous results have shown that elevating SOX1 or SOX2 expression in differentiating ESCs promotes neural differentiation ([@bib83]). In the present study, we showed that ESCs with either elevated SOX2 or SOX3 self-renew efficiently. However, when these cells were placed in an EpiSC differentiation protocol, differentiation was skewed towards a neural identity despite the presence of FGF and neural-antagonising Activin signals ([@bib74], [@bib73]). This indicates that enforced expression of SOXB1 proteins overrides the signalling system that captures primed pluripotent cells in vitro.

Parallels between SOXB1 function during in vitro and in vivo neurogenesis {#s3-5}
-------------------------------------------------------------------------

The dynamics of ESC differentiation in vitro towards neural and EpiSC states show interesting parallels with early development in vivo ([Figure 9](#fig9){ref-type="fig"}). While ESCs and pre-implantation embryos express only *Sox2*, early post-implantation embryos, and differentiating ESCs, express *Sox2* and *Sox3* but not *Sox1* ([@bib77]; [@bib72]; [@bib12]). At gastrulation stages, which are transcriptomically similar to EpiSCs ([@bib34]), *Sox2* and *Sox3* are expressed widely in the epiblast. As noted above, *Sox1* expression is restricted to a subdomain within the *Sox2*/*Sox3*-positive epiblast that overlaps extensively with the prospective brain ([@bib77]; [@bib12]), where early neural differentiation occurs in vivo. Thus, the region expressing all three SOXB1 members might undergo neural induction as a consequence of expressing high levels of SOXB1 proteins, while the rest of the epiblast experiences lower SOXB1 levels, enabling pluripotency to extend through gastrulation ([@bib55]).

An interplay between SOXB1 function and anti-neural signals {#s3-6}
-----------------------------------------------------------

Inhibition of both BMP and Nodal signalling rescues the neural differentiation ability of *Sox2*^+/-^ ESCs. These results suggest that *Sox2*^+/-^ ESCs can initiate exit from naïve pluripotency but cannot complete neural differentiation due to enhanced responses of cells to endogenous anti-neuralising signalling by BMP and Nodal. The viability of *Sox2*^+/-^ mice ([@bib6]; [@bib62]; [@bib21]) indicates that the in vivo environment is able to overcome these anti-neural signals. In wild-type embryos, the prospective brain is shielded from Nodal and BMP signalling by secreted inhibitors of these pathways, including Cer1, Lefty1/2 ([@bib56]), Chrd and Nog ([@bib7]) ([Figure 9](#fig9){ref-type="fig"}). Removal of either Nodal or BMP inhibition leads to absence of anterior neural tissue. Interestingly, the cells that express these inhibitors (including the anterior visceral endoderm and node) do not express SOXB1 proteins and are therefore likely to be functionally unaltered in *Sox2*^+/-^ embryos. The observation that the reduced SOXB1 concentration in *Sox2*^+/-^ pluripotent cells is compatible with neural differentiation, provided that endogenous anti-neuralising signals are blocked, indicates that to fully understand how the choice between neural and primed pluripotency is made, it will be necessary to elucidate how the signalling environment connects to the SOXB1-driven transcriptional programme.

Materials and methods {#s4}
=====================

Cell culture {#s4-1}
------------

For a complete list of cell lines, their name, their genotypes and their original characterisation, see [Supplementary file 2](#supp2){ref-type="supplementary-material"}. All the cell lines used in this study were regularly tested for contaminations and were mycoplasma negative.

ESCs grown in LIF/FCS conditions were cultured on dishes coated with 1% gelatin (Sigma-Aldrich, St. Louis, USA) and in GMEM medium (Sigma-Aldrich, St. Louis, USA) supplemented with 1x non-essential aminoacids (Life Technologies, Waltham, USA), 1 mM sodium pyruvate (Life Technologies, Waltham, USA), 2 mM glutamine (Life Technologies, Waltham, USA), 100 U/ml human LIF ([@bib49]), 10% ESC-grade FCS (APS, UK) and 100 μM β-mercaptoethanol (Life Technologies, Waltham, USA). G418 (200 μg/mL, Sigma-Aldrich, St. Louis, USA) was supplemented to maintain SCKO ESCs.

To adapt ESCs into LIF/2i/N2B27 ([@bib82]) (LIF/2i) or LIF/BMP4/N2B27 ([@bib79]) (LIF/BMP) conditions, ESCs were replated in LIF/FCS on gelatin-coated plates for 24 hr before changing the culture media to N2B27 medium ([@bib80]) supplemented with 100 U/ml LIF, 1 μM PD0325901 (Stemgent, Cambridge, USA) and 3 μM CHIR99021 (Stemgent, Cambridge, USA) (LIF/2i) or 10 ng/ml BMP4 (Life Technologies, Waltham, USA) (LIF/BMP). Cells were passaged for at least four passages before using for analysis.

EpiSCs were derived from LIF/FCS-cultured ESCs as described previously ([@bib26]; [@bib55]) and cultured on dishes pre-coated with 7.5 μg/ml fibronectin (Sigma-Aldrich, St. Louis, USA) without feeders in N2B27 medium ([@bib80]) ActivinA (20 ng/ml, Peprotech, UK), bFGF (10 ng/ml, Peprotech, UK). In brief, ESCs were plated at a density of 3 × 10^3^ cells/cm2; the equivalent of 30 × 10^3^ cells per well of a six well plate. Medium was changed to Activin/FGF conditions 24 hr after replating. Cells were passaged after 4--5 days in a 1:20 dilution for the first 8--10 passages. Stable EpiSC lines were propagated by passaging in a 1:10-1:20 dilution.

For neural differentiation, ESCs were cultured with minor modifications as previously described ([@bib81]; [@bib80]). Briefly, ESCs were replated in LIF/FCS on gelatin-coated plates for 24 hr before changing the culture media to N2B27 medium ([@bib80]) only and allowed to grow for the indicated amount of time. When indicated, cells were differentiated in the presence of bFGF (10 ng/ml, Peprotech, UK), LDN-193189 (100 nM, Stemgent, Cambridge, USA) and/or SB-431542 (10 μM, Merck, Germany).

*Sox2* deletion in ESCs and EpiSCs {#s4-2}
----------------------------------

Sox2 deletion in SCKO ESCs was performed similarly to previously described ([@bib24]; [@bib21]). In brief, 10^7^ SCKO ESCs grown in LIF/FCS conditions were transfected using Lipofectamine 3000 (Life Technologies, Waltham, USA) with 6--15 μg of transgene-expressing plasmid the indicated test cDNA before replated in LIF/FCS at a density of 1.5 × 10^6^ per 10 cm dish cultured overnight in the presence or in the absence of 4-hydroxytamoxifen (1 μM, Sigma-Aldrich, St. Louis, USA). Medium was changed 12 to 24 hr later to LIF/FCS medium supplemented with Hygromycin B (150 μg/mL, Roche, Switzerland). Transfected cells were cultured for 8 to 10 days before they were stained for alkaline phosphatase (AP) activity (Sigma-Aldrich, St. Louis, USA). Stained colonies were scored based on the presence of AP-positive cells within the colony. In parallel, unstained populations were expanded to generate cell lines before genotyping by PCR.

SCKO EpiSCs were transfected with ptdTomato-T2A-Cre by lipofection (Lipofectamine 2000, Life Technologies, Waltham, USA). After 12--24 hours cells were sorted for tdTomato expression and replated in the presence of ROCK inhibitor (Y-27632, Merck, Germany) for 24 hr before medium was changed to remove ROCK inhibitor. Clones were expanded before genotyping by PCR.

CRISPR/Cas9 deletion of the *Sox3* gene {#s4-3}
---------------------------------------

Two sgRNAs were designed upstream of the ATG (sgRNA1) and downstream of the stop codon (sgRNA2) using an online CRISPR Design Tool (<http://crispr.mit.edu/>) and subsequently cloned in the *BbsI*-linearised pSpCas9(BB)−2A-GFP plasmid (Addgene 48138) as previously described ([@bib59]). sgRNA sequences used in this study are listed in [Supplementary file 3](#supp3){ref-type="supplementary-material"}. 10^6^ E14Tg2a ESCs were co-transfected with 1 μg of sgRNA1-encoding plasmid and 1 μg of sgRNA2-encoding plasmid using Lipofectamine 3000 (Life Technologies, Waltham, USA) following the manufacturer's instructions. 24 hr after transfection, GFP-positive cells were sorted by FACS and replated at clonal density to allow the isolation of single colonies. After 8--10 days, single ESC colonies were expanded and the *Sox3* locus was genotyped by PCR.

Indel induction and TIDE analysis {#s4-4}
---------------------------------

SgRNAs targeting the *Sox2* or *Sox3* ORF immediately upstream of the sequence encoding for the HMG box were designed using an online CRISPR Design Tool (<http://crispr.mit.edu/>). The Sox2 sgRNA was subsequently cloned in the *BbsI*-linearised pSpCas9(BB)−2A-Puro (PX459) V2.0 plasmid (Addgene 62988) as previously described ([@bib59]). The resulting plasmid, or the empty vector control, were then transfected using Lipofectamine 3000 (Life Technologies, Waltham, USA) into SCKO ESCs constitutively expressing either SOX1, SOX3 or GFP. After 24 hr, ESCs were selected with 1.5 μg/ml of puromycin (Life Technologies, Waltham, USA) for 24 hr to enrich for transfected cells, and then expanded for 72 hr. For *Sox3* indel analysis, two individual sgRNAs were cloned in *BbsI*-linearised pSpCas9(BB)−2A-mCherry that was obtained by fusing a 2A-mCherry cassette to the Cas9 CDS of the eSpCas9(1.1) plasmid (Addgene 71814). 10^6^ E14Tg2a (*Sox2^+/+^*), SCKO (*Sox2^fl/-^*), SKO1 (*Sox2^-/-^*) and SKO6 (*Sox2^-/-^*) EpiSCs were then transfected with 1 μg of sgRNA-containing plasmids or empty vector using Lipofectamine 3000 (Life Technologies, Waltham, USA). 48 hr after transfection, mCherry-positive cells were FACS sorted, replated and expanded for 72 hr. Genomic DNA (gDNA) was extracted using the DNeasy Blood and Tissue kit (Qiagen, Germany) following the manufacturer's instructions. gDNA was PCR amplified using the Q5 HotStart Polymerase (NEB, Ipswich, USA) and primers flanking either the Sox2 sgRNA or Sox3 sgRNAs recognition sites. Primers and sgRNAs used in this study are listed in [Supplementary file 3](#supp3){ref-type="supplementary-material"}. PCR amplicons were purified and submitted for Sanger sequencing using the same forward primer that they had been generated with. Sanger sequencing electropherograms were then submitted for indel analysis with the TIDE tool (<https://tide-calculator.nki.nl/>, \[[@bib10]\]) using amplicons obtained from cells transfected with empty vector as reference sequences. Indel analysis was performed using the default TIDE settings and a window of 27 bp for SCKO ESCs and Sox2 indel induction, and a window of 30 bp for EpiSCs and Sox3 indel induction. Indels with p value \>0.001 were scored as statistically significant.

PCR genotyping {#s4-5}
--------------

Genomic DNA (gDNA) was extracted from cells using DNeasy kits (Qiagen, Germany) according to the manufacturer's recommended protocol. 100 ng of gDNA was used per PCR reaction. Primers used in this study are listed in [Supplementary file 3](#supp3){ref-type="supplementary-material"}.

Plasmid constructs {#s4-6}
------------------

A mouse genomic BAC containing 5 kb on either side of the *Sox2* stop codon (Source bioscience bMQ314D22) was shredded by pSC101-BAD-gbaA mediated recombineering using the pACYC177 backbone comprising the p15-origin and β-lactamase gene to produce pSox2-10kb. To construct the Sox2-T2A-H2B-tdTomato-IRES-Neo cassette, 89 bp and 168 bp immediately upstream and downstream of, and excluding the *Sox2* stop codon were PCR amplified to serve as homology arms for recombineering. The 89 bp upstream fragment has a 5' *Xho* I site and a GSG-T2A sequence at the 3' end containing an in-frame *Fse* I site that preserves the T2A Gly-Pro residues and is followed by *Not* I, *Pac* I, *Asc* I, *San* DI, *Bam* HI, *Afl* II, *Nhe* I, *Cla* I and *Xho* I sites. The sequence of this fusion is shown below:

GGCTCCGGAGAGGGCAGAGGAAGTCTGCTAACATGCGGTGACGTCGAGGAGAATCCTGGGCCGGCCGCGGCCGCTTAATTAAGGCGCGCCGGGACCCGGATCCGCTTAAGGCTAGCATCGATTCTCGAG

The 89 bp fragment was cloned into a PCR amplified, pUC19-derived 2 kb minimal vector comprising β-lactamase gene and Col E1 origin with 150nt flanking sequences and a single *Xho* I site (pL). Individual features were PCR-amplified, flanked with unique sites and cloned as follows: H2B-tdTomato was cloned in-frame between *Fse* I and *Not* I, using TAA stop codon from *Pac* I; Gtx-IRES was cloned between *Pac* I and *Asc* I; neomycin phosphotransferase (Npt) was cloned between *San* DI and *Bam* HI, using the TAA stop codon from *Afl* II. The 168 bp downstream fragment is flanked with *Nhe* I at the 5' side and *Cla* I at the 3' end and was cloned between *Nhe* I and *Cla* I (pL-Sx-5HTiN3).

To insert a selection cassette for use in recombineering and targeting, a linker was made by annealing the following two oligonucleotides:

TCGAGCTTAAGGTCGACAGATCTCGATCGGCTAGCC

TCGAGGCTAGCCGATCGAGATCTGTCGACCTTAAGC

The linker was cloned into the *Xho* I site of a pTOPO-BluntII-derived, Zeocin-resistant version of pL (pZ-Linker). A 3.6 kb *Bam* HI fragment containing PGK-EM7-Npt-pA and MC1-HSVtk-pA flanked by FRT sites (FNF) was subcloned from pBS-M179 (a kind gift from Dr. Andrew Smith) into the *Bgl* II site of pZ-Linker (pZ-FNF), destroying the *Bam* HI and *Bgl* II sites. This places an *Afl* II site on one side and *Nhe* I site on the other side of the FNF cassette and these are used to subclone into pL-Sx-5HTiN3 to make pL-Sx-5HTiNFNF3.

To make the targeting vector, a 7.1 kb *Xho* I-*Cla* I fragment from pL-Sx-5HTiNFNF3 was transfected into *E. coli* containing pSox2-10kb and pSC101-BAD-gbaA to replace the *Sox2* stop codon by recombineering. Successful kanamycin-resistant recombinants carrying a 20 kb targeting vector (pSox2AHTiN-FNF-10kb) were amplified at 37°C to restrict pSC101-BAD-gbaA replication and identified by diagnostic *Bam* HI digest.

The targeting construct was linearised, electroporated into E14Tg2a ESCs and G418 resistant colonies expanded and genotyped by southern blot analysis as described below. The FRT-flanked cassette was removed by transiently transfecting pPGK-FlpO into verified E14[T]{.ul}G2a-derived [S]{.ul}ox2-td[T]{.ul}omato ESC clone 18 (TST18).

Overexpression constructs were generated by cloning open reading frames (ORFs) of indicated Sox genes, preceeded upstream by the Kozak consensus sequence (GCCGCCACC), into pPyCAG-*IRES*-Hyg vector between the *Xho*I and *Not*I sites ([@bib13]).

Southern blot analysis {#s4-7}
----------------------

40 µg of genomic DNA were digested with *Eco* RI (5' probe analysis) or with *Hind* III (3' and internal probe analysis) and assessed by Southern blot analysis using probes synthesised by PCR from the oligonucleotides indicated in [Supplementary file 3](#supp3){ref-type="supplementary-material"}.

RNA level quantification {#s4-8}
------------------------

Total RNA was purified from cells using RNeasy mini kits (Qiagen, Germany) following the manufacturer's protocol. cDNA was prepared from 1 μg of total RNA using SuperScript III reverse transcription kits (Life Technologies, Waltham, USA) according to the recommended protocol and the final cDNA solution was diluted 1:10 prior to use. 2 μl of cDNA solution was used per reaction with the Takyon Sybr Assay (Eurogentec, Belgium). Primers used in this study are listed in [Supplementary file 3](#supp3){ref-type="supplementary-material"}.

Microarray gene expression analysis {#s4-9}
-----------------------------------

Total RNA (127 ng/sample) from three independently replicated experiments was converted into biotin-labelled cRNA using the Illumina TotalPrep RNA amplification kit (Ambion, Cambridge, USA). Microarray hybridization reactions were performed on a Mouse WG-6v2 BeadChip (Illumina). Raw data were normalised in R using the beadarray ([@bib18]), limma ([@bib65]) and sva ([@bib41]) packages from the Bioconductor suite ([@bib25]). Briefly, low-quality probes were removed from the input and data were then quantile-normalized. ComBat was used to account for batch effects ([@bib41]) between microarrays run at different dates. Differential expression in the log2-transformed data was assessed with the limma algorithms ([@bib65]). Probes were considered differentially expressed if they showed a FDR-adjusted p-value of ≤ 0.1 and an absolute log~2~ fold change ≥ log2(1.5). Primary analysis results were uploaded to GeneProf ([@bib27]) and mapped to Ensembl-based reference genes, collapsing multiple probes for the same gene by picking the most responsive probe (i.e., the probe with the highest absolute fold change across all pair-wise comparisons). Data are available in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Microarray data have been submitted to the Gene Expression Omnibus (GEO) under accession code GSE99185. 

Immunofluorescence staining {#s4-10}
---------------------------

Cells were fixed with 4% PFA (10 mins, RT) and permeabilised using PBS/0.1% (v/v) Triton-X100 (PBSTr) for 10 mins, before quenching with 0.5M Glycine/PBSTr (15 mins). Non-specific antigens were blocked using 3% (v/v) donkey serum/1% (v/v) BSA/PBSTr (1 hr, RT) before incubating with primary antibody in blocking solution (4°C, overnight). Cells were washed with PBSTr before incubating with donkey-raised secondary antibodies conjugated with Alexa-488,--568 or −647 in blocking solution (1--2 hr, RT). DAPI (1--2 μg/mL, Molecular Probes) in PBS was added to cells for at least 30 mins before imaged using the Olympus IX51 inverted fluorescent microscope. Primary antibodies used were: α-SOX2 (1:400; Abcam ab92494, UK ), α-NANOG (1:500; eBioscience 14--5761, Cambridge, USA) and α-OCT4 (1:400; Santa Cruz Biotechnology sc8628, Santa Cruz, USA), α-SOX3 antibody (1:400; Abcam ab42471, UK ), α-βIII-tubulin (1:1500; Covance MMS-435P, Princeton, USA ).

Immunoblotting analysis {#s4-11}
-----------------------

Cells were lysed with lysis buffer comprising 50 mM Tris pH 8.0, 150 mM NaCl supplemented with fresh 0.5% NP-40, 0.5 mM DTT, 1 × protease inhibitors cocktail (Roche, Switzerland) and 1.3 μl of Benzonase (Novagen, Germany) (1 hr, 4°C). Samples were prepared by boiling 40 μg of total protein extract with Laemmli buffer (Life Technologies, Cambridge, USA) . Samples were analysed using Bolt 10% Bis-Tris +SDS PAGE (Life Technologies, Cambridge, USA) and electroblotted onto 0.2 µm pore Whatman-Protran nitrocellulose membranes (Capitol Scientific, Austin, USA) in transfer buffer comprising 25 mM Tris/0.21M glycine/20% methanol. Membranes were blocked using 5% (w/v) low-fat milk in 0.01% (v/v) Tween-20/PBS (PBSTw) before incubating with primary antibody in blocking solution . Membranes were washed with PBSTw before incubating with donkey-raised secondary antibodies conjugated with IRDye 800CW (1:10000; LI-COR 926--32213, Lincoln, USA) and HRP-conjugated α-βActin (1:10000; Abcam ab20272, UK) antibody. HRP-staining was developed using a Super-signal West Pico kit (Pierce, Cambridge, USA) before imaging the membranes using LI-COR Odyssey Fc imager. The primary antibodies used were: α-Sox2 (1:1000; Abcam ab92494, UK) and α-Nanog (1:2000; Bethyl Laboratories A300-397A, Montgomery, USA).

Embryo manipulation {#s4-12}
-------------------

Mice were maintained on a 12 hr light/dark cycle. All animals were maintained and treated in accordance with guidance from the UK Home Office. Embryonic day (E)0.5 was designated as noon on the day of finding a vaginal plug. Morula aggregations, blastocyst injections and embryo transfer were performed using standard procedures. Chimeric, gastrulation-stage embryos were collected at E7.5 and imaged using an inverted fluorescence microscopy. Chimeric E9.5 embryos were fixed with 4% PFA at 4°C for 3 hr and cryosectioned as described before ([@bib78]). Sections were stained for GFP as described above.
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The following dataset was generated:

Corsinotti AWong FCKTatar TSzczerbinska IHalbritter FColby DGogolok SPantier RLiggat KMirfazeli EHall-Ponsele EMullin NWilson VChambers I2017Distinct SoxB1 networks are required for naïve and primed pluripotency<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99185>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE99185)

10.7554/eLife.27746.033

Decision letter

Pera

Martin

Reviewing Editor

University of Melbourne

Australia

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Distinct SoxB1 networks are required for naive and primed pluripotency\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Sean Morrison as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Essential revisions:

All reviewers agree that the study has been carefully performed and contains some important findings about the role of Sox genes in pluripotency. However, there is much previous work pertinent to the study which is not cited in the manuscript. This omission should be addressed, and the relevant findings discussed in light of the authors\' work. You should also discuss the ways in which in vivo findings are at odds with the in vitro findings and why you have confidence that the differences do not simply reflect in vitro artifacts.

Specific comments:

This aim of this work is to address the role of SOXB1 factors in epiblast stem cell (EpiSC) pluripotency. The authors show that Sox2 can be deleted from EpiSCs without affecting their potential, which is due to functional redundancy with Sox3. This is claimed to be a surprising result, but it is really quite predictable, given the co-expression of the two genes, and that they are known to be functionally equivalent (see for example: https://www.ncbi.nlm.nih.gov/pubmed/28515211;https://www.ncbi.nlm.nih.gov/pubmed/10446282), with Sox3 at slightly higher levels and slightly more extensively expressed than Sox2. Indeed, compared to the mouse, the two genes have swapped prominence in the chick embryo, with Sox3 preceding Sox2, and with both acting in the same way antagonistically to Snail, in helping to promote ectoderm/neurectoderm development during gastrulation (https://www.ncbi.nlm.nih.gov/pubmed/21920318).

The authors show that Sox3 can also be deleted from EpiSCs without eliminating self-renewal. Again, this is not surprising, given that Sox3 null mutant mice are viable (https://www.ncbi.nlm.nih.gov/pubmed/14981518; https://www.ncbi.nlm.nih.gov/pubmed/17728342; https://www.ncbi.nlm.nih.gov/pubmed/28515211).

Deletion of both Sox2 and Sox3 was found to prevent self-renewal of EpiSCs. This is again not surprising, but it is probably worth showing.

The authors also found that differentiation of Sox2 heterozygous ESCs is compromised, although this would seem not to be very important in vivo, given that such cells can make germ line chimeras after blastocyst injection and that both Sox2 heterozygous mice and humans are viable (although with a range of more or less severe defects) \[many papers\]. The authors also show that increased SOXB1 levels divert the ESC to EpiSC transition towards neural differentiation.

Putting all their findings together, they claim that optimal SOXB1 levels are critical for each pluripotent state and for cell fate decisions during exit from naïve pluripotency.

While I have few if any problems with the way the experiments have been conducted, indeed some approaches are clever, such as the indel analysis after CRISPR/Cas9 NHEJ mutagenesis, the authors seem to disregard much published data including all that on the effects of mutations in Sox2, Sox3 (and Sox1) in vivo, where there is extensive data both in mice and humans. Several of the in vivo findings are at odds with the claims being made here for the role of Soxb1 genes in ESCs and EpiSCs in vitro. This begs the question as to the relevance of this current work. If the authors had gone on to define the downstream genes required for neurectoderm, etc., fate, or the mechanisms involved in crosstalk or feedback regulation between Sox2 and Sox3, then this would be important. But as it is, I worry that they are mostly chasing some in vitro artifacts.

Other comments:

It is usual convention to write protein symbols as all uppercase letters (both mouse and human proteins).

Introduction, third paragraph: Where is the evidence for 23 SOX proteins in mammals? It is usually accepted that there are 20.

Subsection "A subset of SOX family proteins can functionally replace *Sox2* in ESC self-renewal", first paragraph and [Figure 2](#fig2){ref-type="fig"}: Sox15 was already known to be able to substitute for Sox2 in pluripotency. https://www.ncbi.nlm.nih.gov/pubmed/27582319

Subsection "Sox3 is dispensable for pluripotent cell self-renewal", first paragraph and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}: The level of Sox3 in undifferentiated ES cells is extremely low -- but it is readily activated by retinoic acid and other ligands.

\"These findings indicate that Sox3 is dispensable for ESC self-renewal.\" This was also known from previous work from others where Sox3 null mutant ESCs have been generated (gene targeting via homologous recombination) and the generation of mice from these (https://www.ncbi.nlm.nih.gov/pubmed/14981518;https://www.ncbi.nlm.nih.gov/pubmed/14585968).

\"These data demonstrate that both naïve and primed pluripotent cells can self-renew in the absence of Sox3.\" Again, this is not surprising given the viability of Sox3 null mice.

Subsection "*Sox2* is dispensable for the maintenance of primed pluripotency", last paragraph: Sox3 mRNA levels were found to be elevated in in *Sox2*^-/-^ EpiSCs compared to controls. Again, this has been seen before in the developing brain in vivo (https://www.ncbi.nlm.nih.gov/pubmed/18638478).

\"These data indicate that a Sox2 level above that present in *Sox2^fl/-^*ESCs is required to enable neural differentiation and suggest that below this *SOX2* concentration cells are directed towards non-neural differentiation via an early post-implantation identity ([Figure 6A](#fig6){ref-type="fig"}).\" This does not make sense since *Sox2*^+/-^ mice (and humans) do have a CNS, although with some abnormalities. Is the *Sox2^fl^* allele hypomorphic?

\"While *Sox2^fl/-^*ESCs do not effectively undergo neural differentiation ([Figure 6](#fig6){ref-type="fig"}), quantitative transcript analysis shows that deletion of Sox3 from *Sox2^fl/-^*ESCs is sufficient to rescue the neural differentiation of the cells..\" I don\'t understand this. And again, it doesn\'t relate very well to the in vivo situation.

-- \"In the future, it will also be interesting to determine the extent to which SoxB1 proteins can substitute for Sox2 function in vivo.\" Some such combinations have already been carried out:https://www.ncbi.nlm.nih.gov/pubmed/15882093https://www.ncbi.nlm.nih.gov/pubmed/28515211

Discussion, fourth paragraph: This paper, which also shows co-expression and some functional redundancy of Sox2 and Sox3, should perhaps also be cited in relevant places: https://www.ncbi.nlm.nih.gov/pubmed/12514105

10.7554/eLife.27746.034

Author response

> Essential revisions:
>
> All reviewers agree that the study has been carefully performed and contains some important findings about the role of Sox genes in pluripotency. However, there is much previous work pertinent to the study which is not cited in the manuscript. This omission should be addressed, and the relevant findings discussed in light of the authors\' work. You should also discuss the ways in which in vivo findings are at odds with the in vitro findings and why you have confidence that the differences do not simply reflect in vitro artifacts.

We are pleased that our reviewers agree that our work has been carefully conducted and has produced important results about the function of Sox genes in pluripotency. We acknowledge that we omitted discussion of several important and relevant previous publications and are grateful to the reviewers for drawing our attention to these omissions. As a consequence, we have considerably redrafted our Discussion to include this published work in the context of our findings. Moreover, in response to our reviewers prompting, we have now performed additional experiments that we think resolve the apparent discrepancy between published in vivo studies and our in vitro work. We believe our current manuscript has been significantly improved in response to our reviewers' request and we hope that it is now considered suitable for publication.

> Specific comments:
>
> This aim of this work is to address the role of SOXB1 factors in epiblast stem cell (EpiSC) pluripotency. The authors show that Sox2 can be deleted from EpiSCs without affecting their potential, which is due to functional redundancy with Sox3. This is claimed to be a surprising result, but it is really quite predictable, given the co-expression of the two genes, and that they are known to be functionally equivalent (see for example: https://www.ncbi.nlm.nih.gov/pubmed/28515211;https://www.ncbi.nlm.nih.gov/pubmed/10446282), with Sox3 at slightly higher levels and slightly more extensively expressed than Sox2.

We are grateful to the reviewer for pointing us to the Adikusuma et al. paper, an elegant study published while our manuscript was under review, which shows that knock-in of Sox2 to the Sox3 locus can rescue pituitary and testis defects of the Sox3 knockout. We refer to this work as indicated below (Introduction, last paragraph and subsection "SOXB1 redundancy in vivo"). The second paper referred to above is Wood and Episkopou, a classic RNA in situ hybridisation study that we have cited in our manuscript and that shows overlapping Sox2 and Sox3 expression domains in the post-implantation epiblast. We accept the reviewer's point that these overlapping expression domains, together with other studies referred to later by the reviewer are sufficient to suggest our findings are unsurprising. Therefore, we have deleted the relevant instances of 'surprising' from our manuscript and reframed our discussion in light of the papers that the reviewer has kindly brought to our attention. However, neither of the studies above, nor any of the studies that the reviewer refers to below have tested the functional redundancy of Sox2 and Sox3 in postimplantation pluripotency and therefore our results are novel.

We have reserved the use of the word 'surprising' in the revised manuscript for the unexpected up-regulation of Sox2 mRNA upon deletion of Sox3, rescuing neural differentiation of *Sox2*^+/-^ cells and indicating a novel cross-regulatory relationship between the SoxB genes (subsection "[Modulating SOXB1 levels affects differentiation and can prevent capture of primed pluripotency, fifth paragraph]{.ul} and subsection "Low SoxB1 levels permit entry to the EpiSC state").

> Indeed, compared to the mouse, the two genes have swapped prominence in the chick embryo, with Sox3 preceding Sox2, and with both acting in the same way antagonistically to Snail, in helping to promote ectoderm/neurectoderm development during gastrulation (https://www.ncbi.nlm.nih.gov/pubmed/21920318).

We agree this is relevant background and have included a reference to the Acloque paper in the Discussion, 'in the chick, Sox2 and Sox3 both promote development of ectoderm and neurectoderm at gastrulation, although interestingly, in this case Sox3 expression occurs before Sox2 (Acloque et al.).'

> The authors show that Sox3 can also be deleted from EpiSCs without eliminating self-renewal. Again, this is not surprising, given that Sox3 null mutant mice are viable (https://www.ncbi.nlm.nih.gov/pubmed/14981518; https://www.ncbi.nlm.nih.gov/pubmed/17728342; https://www.ncbi.nlm.nih.gov/pubmed/28515211).

The papers referred to are Rizzoti et al. (shows Sox3 is required for pituitary function), Rizzoti & Lovell-Badge (shows that Sox3 is required for correct craniofacial morphogenesis) and Adikusuma et al. (knock-in of Sox2 to the Sox3 locus referred to above). While each of these papers indicates that *Sox3*-null mice can be viable and that therefore there may not be an essential requirement for Sox3 in the epiblast, there are suggestions that things may not be so simple.

Rizzotti et al. (2004) state as an unpublished observation that there is early gastrulation lethality of Sox3 on 129 genetic background and that a viable phenotype was only observed in conditional nulls on an outbred background. Adikusuma et al. also report failure to generate Sox3^Sox2KI^ mice from targeted clones via conventional gene targeting in ES cells, followed by blastocyst injection of these cells. Subsequently, Adikusuma et al. obtained the *Sox3^Sox2KI^* allele using a CRISPR/Cas9 strategy via pronuclear injection of C57Bl/6 zygotes. The failure of two independent groups to establish mice from knock-out Sox3 on a 129 background points to a requirement for Sox3 that goes beyond the reported viability on an outbred background.

We have shown that Sox3 contributes to the total SoxB1 levels required for postimplantation pluripotency ([Figure 5](#fig5){ref-type="fig"}). This suggests that subtle strain-specific variations in Sox2 levels/timing in postimplantation embryos may exist, which permit maintenance of Sox3 KO ES cells but not embryos.

> Deletion of both Sox2 and Sox3 was found to prevent self-renewal of EpiSCs. This is again not surprising, but it is probably worth showing.

We agree that despite other reports of tissues where Sox2 and Sox3 are redundant, our finding that Sox2 and Sox3 act redundantly in EpiSC self-renewal is worthwhile, especially as it highlights a distinct post-implantation-specific functional PGRN. Moreover, our results point to a model wherein both genes contribute to maintain threshold SoxB1 levels required for postimplantation pluripotency -- as alluded to by Avilion et al. This information is contained in the updated model ([Figure 9](#fig9){ref-type="fig"}).

> The authors also found that differentiation of Sox2 heterozygous ESCs is compromised, although this would seem not to be very important in vivo, given that such cells can make germ line chimeras after blastocyst injection and that both Sox2 heterozygous mice and humans are viable (although with a range of more or less severe defects) \[many papers\]. The authors also show that increased SOXB1 levels divert the ESC to EpiSC transition towards neural differentiation.
>
> Putting all their findings together, they claim that optimal SOXB1 levels are critical for each pluripotent state and for cell fate decisions during exit from naïve pluripotency.
>
> While I have few if any problems with the way the experiments have been conducted, indeed some approaches are clever, such as the indel analysis after CRISPR/Cas9 NHEJ mutagenesis, the authors seem to disregard much published data including all that on the effects of mutations in Sox2, Sox3 (and Sox1) in vivo, where there is extensive data both in mice and humans. Several of the in vivo findings are at odds with the claims being made here for the role of Soxb1 genes in ESCs and EpiSCs in vitro. This begs the question as to the relevance of this current work. If the authors had gone on to define the downstream genes required for neurectoderm, etc., fate, or the mechanisms involved in crosstalk or feedback regulation between Sox2 and Sox3, then this would be important. But as it is, I worry that they are mostly chasing some in vitro artifacts.

We apologise for omitting important in vivo studies in our previous manuscript. We have taken on board the reviewers' suggestions and have now discussed previous in vivo findings in relation to our results (we have indicated these in response to detailed points elsewhere in this document).

To address whether we were indeed chasing an artefactual inability of SCKO to undergo neural differentiation, we independently generated *Sox2*^+/-^ ESCs using CRISPR. Two new *Sox2*^+/-^ ESC clones derived independently using two different sgRNAs confirmed our findings that mutation of a *Sox2* allele in ESCs causes a defect in neural differentiation ([Figure 7](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Whether this was due to Sox2 protein level being insufficient to drive neural differentiation remained an open question that we have addressed as outlined below.

in vitro findings can highlight cellular requirements that are difficult to unpick in vivo. A key difference between in vitro and in vivo experiments is the ability to control the extracellular environment. Through in vitro studies using inhibitors of BMP and Nodal signalling, we have uncovered endogenous BMP and Nodal signalling in Sox2 heterozygous cells that block neural differentiation ([Figure 7](#fig7){ref-type="fig"}). This establishes that the inability of *Sox2*^+/-^ ESCs to undergo neural differentiation is not an intrinsic cellular defect, but is due to an anti-neural environment. In the embryo, such an environment exists in the anterior epiblast and does not depend on Sox2. We believe these experiments resolve the apparent discrepancy between our findings and the ability of *Sox2*^+/-^ mice to develop brains.

> Other comments:
>
> It is usual convention to write protein symbols as all uppercase letters (both mouse and human proteins).

We have corrected the text so that all reference to proteins is uppercase.

> Introduction, third paragraph: Where is the evidence for 23 SOX proteins in mammals? It is usually accepted that there are 20.

We apologise for this error, which has been corrected (Introduction, third paragraph).

> Subsection "A subset of SOX family proteins can functionally replace Sox2 in ESC self-renewal", first paragraph and [Figure 2](#fig2){ref-type="fig"}: Sox15 was already known to be able to substitute for Sox2 in pluripotency. https://www.ncbi.nlm.nih.gov/pubmed/27582319

We have cited the Niwa et al. study but have added a further citation to this work relevant to SOX15 (subsection "A subset of SOX family proteins can functionally replace Sox2 in ESC self-renewal", first paragraph).

> Subsection "Sox3 is dispensable for pluripotent cell self-renewal", first paragraph and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}: The level of Sox3 in undifferentiated ES cells is extremely low -- but it is readily activated by retinoic acid and other ligands.

We have amended the text (subsection "Sox3 is dispensable for both naïve and primed pluripotency", first paragraph) to draw attention to the low Sox3 expression level observed in ESCs and to our intention to document whether this was required for ESC self-renewal.

> \"These findings indicate that Sox3 is dispensable for ESC self-renewal.\" This was also known from previous work from others where Sox3 null mutant ESCs have been generated (gene targeting via homologous recombination) and the generation of mice from these (https://www.ncbi.nlm.nih.gov/pubmed/14981518;https://www.ncbi.nlm.nih.gov/pubmed/14585968).

The papers referred to above are Rizzoti et al. and Weiss et al. Both papers document the existence of ESCs carrying *loxP*-flanked *Sox3* alleles but do not document deletion of either of these *loxP*-flanked *Sox3* alleles in ESCs. Rizzoti et al. do refer to unpublished data in which a null mutation in Sox3 was targeted to the *Sox3* allele in XY male ESCs. We have therefore amended our text to reflect this ("These findings indicate that Sox3 is dispensable for ESC self-renewal, confirming previously reported unpublished data (Rizzoti et al)").

> \"These data demonstrate that both naïve and primed pluripotent cells can self-renew in the absence of Sox3.\" Again, this is not surprising given the viability of Sox3 null mice.

The reviewer raises an interesting point. Rizzoti et al. state that "To study the role of Sox3, we targeted null mutations in the gene into XY embryonic stem (ES) cells, but injection of these cells into blastocysts resulted in early lethality of the chimeras due to a gastrulation defect (unpublished data)." The authors circumvented this problem by generating a *loxP*-flanked *Sox3* allele and testing the effects of Sox3 deletion in an outbred background. Rizzoti et al.'s unpublished data suggests in fact that Sox3 may in fact be required in postimplantation pluripotent cells in specific genetic backgrounds (in this case, 129sv/ev). Interestingly, genetic background effects do modulate the severity of Sox3 phenotypes since *Sox3*-null mice have a more severe pituitary phenotype on a C57Bl/6 background (Adikusuma et al.) than on an MF1 background (Rizzoti et al.)

We discussed the points raised by these papers in the Discussion (subsection "SOXB1 redundancy in vivo").

> Subsection "Sox2 is dispensable for the maintenance of primed pluripotency", last paragraph: Sox3 mRNA levels were found to be elevated in in Sox2^-/-^ EpiSCs compared to controls. Again, this has been seen before in the developing brain in vivo (https://www.ncbi.nlm.nih.gov/pubmed/18638478).

This paper by Miyagi et al. shows that Sox3 mRNA is increased in *Sox2*-null E14.5 brain, suggesting that functional compensation between Sox2 and Sox3 occurs in neural stem cells. We have included citation of the work of Miyagi et al. and have amended the text accordingly (subsection "Sox2 is dispensable for the maintenance of primed pluripotency", last paragraph).

> \"These data indicate that a Sox2 level above that present in Sox2^fl/-^ ESCs is required to enable neural differentiation and suggest that below this SOX2 concentration cells are directed towards non-neural differentiation via an early post-implantation identity ([Figure 6A](#fig6){ref-type="fig"}).\" This does not make sense since Sox2^+/-^ mice (and humans) do have a CNS, although with some abnormalities.

We agree with the reviewers' comment and have amended the text (subsection "Modulating SOXB1 levels affects differentiation and can prevent capture of primed pluripotency", second paragraph) to underline that our findings are referring to the differentiation potential of ESCs in vitro, and that this does not exclude compensation mechanisms in vivo. As mentioned above, we have now investigated the neural differentiation phenotype further and believe we can suggest an explanation for this discrepancy based on their increased BMP/Nodal signalling activity.

> Is the Sox2^fl^ allele hypomorphic?

mRNA and protein expression analysis in this ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}, [Figure 8](#fig8){ref-type="fig"}) and previous studies (Gagliardi et al. 2013) suggests that *Sox2*^+^/- cells express about 50-60% of the Sox2 mRNA/protein levels found in WT cells. The validation of the neural differentiation defect of *Sox2*^+/-^ ESCs using ESC clones derived by introducing small deletions in the Sox2 CDS by CRISPR indicates that this defect is not peculiar to the SCKO ESC line.

> \"While Sox2^fl/-^ ESCs do not effectively undergo neural differentiation ([Figure 6](#fig6){ref-type="fig"}), quantitative transcript analysis shows that deletion of Sox3 from Sox2^fl/-^ ESCs is sufficient to rescue the neural differentiation of the cells..\" I don\'t understand this. And again, it doesn\'t relate very well to the in vivo situation.

We have dealt with the apparent differences between the Sox2 heterozygote phenotype in vitro and in vivo above. To clarify the statement, we have added text (subsection "Modulating SOXB1 levels affects differentiation and can prevent capture of primed pluripotency"). This indicates that removal of Sox3 from *Sox2^fl/-^*ESCs increases Sox2 expression to wild-type levels, and Sox1 expression to 10x the wild-type level. This could explain why *Sox2^fl/-^*Sox3null ESCs can differentiate into neurons. This effect is rather surprising given the low expression level of Sox3 relative to *Sox2* in ESCs. This suggests that small alterations in feedback between SoxB1 genes may be sufficient to rescue neural differentiation.

> \"In the future, it will also be interesting to determine the extent to which SoxB1 proteins can substitute for Sox2 function in vivo.\" Some such combinations have already been carried out: https://www.ncbi.nlm.nih.gov/pubmed/15882093https://www.ncbi.nlm.nih.gov/pubmed/28515211

These papers refer to a Sox1knock-in at Sox2 (Ekonomou et al.) and the Sox2 knock-in at Sox3 mentioned earlier (Adikusuma et al.). We have discussed these findings in the "Discussion" section "SOXB1 redundancy in vivo", ending with a modified version of the sentence above; "Further studies will be required to establish the extent to which SOXB1 proteins can substitute genetically for one another in pluripotent cells in vivo."

> Discussion, fourth paragraph: This paper, which also shows co-expression and some functional redundancy of Sox2 and Sox3, should perhaps also be cited in relevant places: https://www.ncbi.nlm.nih.gov/pubmed/12514105

This paper by Avilion et al. is the seminal Sox2 deletion study. In this paper the authors discuss the Sox2 phenotype in relationship to expression of Sox2 and Sox3 and hypothesise that the failure of *Sox2*-null embryos early in development is due to the fact that no other SoxB1 gene is active as early. This is hypothesized to be a general point that SoxB1 phenotypes occur in cells where the particular SoxB1 gene mutated is the sole expressed member of the SoxB1 group. These are important ideas and we have now properly referred to them in our manuscript.
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